
S21E25: Who Really Wins When Weed Goes Mainstream?
Send us Fan Mail Cannabis just moved from Schedule I to Schedule III - and the biggest implications have nothing to do with lifestyle or politics. In this episode of Market Outsiders, Jenny Rae and Namaan break down what reclassification means for the market: who benefits, who loses, and why cannabis stocks dropped on “good” news. They unpack the real unlocks behind the headlines - Medicare and Medicaid eligibility, federally funded research, banking access, and why Big Pharma, consumer giants, and even beer companies may now have the edge. This is a regulatory shock case study: how one policy change reshapes competition, pricing power, supply chains, and long-term winners across healthcare and consumer markets. Partner Links: Learn more about NordStellar's Threat Exposure Management Program; unlock 10% off with code SIMPLIFIED-10 Chapters: 01:05 - What Cannabis Reclassification Actually Changes 03:15 - Schedule I vs Schedule III: Why It Matters 05:45 - Banking, Taxes, and the Industry’s Hidden Constraints 08:20 - Medicare, Medicaid, and the Real Demand Unlock 11:10 - Why Cannabis Stocks Fell on “Good” News 13:30 - Big Pharma, Big Beer, and New Market Entrants 19:40 - Supply Chains, Compliance, and Rising Costs 25:00 - Who Wins, Who Loses, and What Comes Next Connect With Management Consulted Create a free MC account or download the MC app (Apple, Android) to start your prep today Schedule a free 15min consultation with the MC Team Watch the video version of the podcast on YouTube Follow us on LinkedIn, Instagram, and TikTok Join an upcoming live event - case interviews demos, expert panels, and more
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
